Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.47 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.44 |
| ▸ | HTR3B | O95264 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.44 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 3/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.39 |
| ▸ | RAF1 | P04049 | 3/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.38 |
| ▸ | BRAF | P15056 | 2/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL881834 | 0.84 | HTR3E (0.56) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL5416223 | 0.81 | HSP90AA1 (0.49) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL23270232 | 0.79 | HTR3E (0.44) | ARHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL5668761 | 0.78 | PPARG (0.52) | ARKDRCHEK2RAF1CDK8 | |
| SCHEMBL6511184 | 0.76 | MAOA (0.50) | ARHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL18235652 | 0.76 | AR (0.49) | ARKDRCHEK2RAF1HDAC3 | |
| SCHEMBL876272 | 0.76 | AR (0.49) | ARKDRCHEK2RAF1HDAC3 | |
| SCHEMBL23270216 | 0.76 | HTR3E (0.44) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL15563090 | 0.76 | CA1 (0.45) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL30543087 | 0.76 | CA1 (0.45) | HTR3EHTR3BHTR3AHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210290597-A1 | METHOD OF TREATING A CONDITION ASSOCIATED WITH NEURODEGENERATION USING INHIBITORS OF OAT3 | NEUROPORE THERAPIES, INC. (US) | 2021-09-23 | — | — | US | disclosed |
| US-20210290597-A1 | METHOD OF TREATING A CONDITION ASSOCIATED WITH NEURODEGENERATION USING INHIBITORS OF OAT3 | NEUROPORE THERAPIES, INC. (US) | 2021-09-23 | — | — | US | disclosed |
| EP-3810133-A1 | METHOD OF TREATING A CONDITION ASSOCIATED WITH NEURODEGENERATION USING INHIBITORS OF OAT3 | Neuropore Therapies, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| CN-112512523-A | Methods of treating conditions associated with neurodegenerative disorders using inhibitors of OAT3 | 神经孔疗法股份有限公司 | 2021-03-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210290597-A1 | METHOD OF TREATING A CONDITION ASSOCIATED WITH NEURODEGENERATION USING INHIBITORS OF OAT3 | OAT, CLN6, SLC2A3 | AR 4706/4885HTR3E 738/4885HTR3B 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.